ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/PSMA
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/PSMA
15
trial(s) found.
NCT06909825
Advanced
Phase 2
Recruiting
A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) (
FPI-2265-203
)
PARP inhibitor
radioligand,PSMA-targeting
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4509 - North Lakes - Icon Cancer Centre North Lakes
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06879041
Advanced
Phase 1
Recruiting
A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer (
D7580C00001
)
radioligand,PSMA-targeting
Castrate-resistant prostate cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06492122
Radonc
Phase 1
Recruiting
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of [225Ac]Ac-FL-020 in Participants With mCRPC. (
FL-020-001
)
anit-PSMA radionucleotide-drug conjugate,PSMA-targeting
Castrate-resistant prostate cancer
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6150 - Murdoch - St John of God Murdoch Hospital
NCT05983198
Radonc
Phase 1 / Phase 2
Recruiting
SatisfACtion
: Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With mHSPC and Heavily Pre-treated PSMA-positive mCRPC, With/Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy
radioligand,PSMA-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT05939414
Radonc
Phase 3
Recruiting
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC) (
PSMA-DC
)
radioconjugate,PSMA-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05720130
Radonc
Phase 1 / Phase 2
Recruiting
Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study). (
TheraPb-ADVC001
)
radioligand,PSMA-targeting
Castrate-resistant prostate cancer
Prostate cancer
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05519449
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (
PSMA-007-001
)
PSMA-tumor-activated T-cell engager
Castrate-resistant prostate cancer
Prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT04876651
Radonc
Phase 3
Recruiting
A Multinational, Multicenter, Prospective, Randomized, Controlled, Open Label Phase 3 Study With Best Standard of Care With and Without 177Lu-DOTA-rosopatamab for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug (
177Lu-TLX591-002
)
radioligand,PSMA-targeting
Prostate cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04769817
Radonc
Recruiting
Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) Prospective Patient Registry of Men Treated With PSMA Theranostics (
PMC-20-164
)
Lu-177 vipivotide tetraxetan
cancer therapy
cancer therapy,PSMA-targeting
radioconjugate,PSMA-targeting
+ cancer therapy,PSMA-targeting
Castrate-resistant prostate cancer
Prostate cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04597411
Radonc
Phase 1
Recruiting
AcTION: A Phase I Study of [225Ac]Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer With or Without Prior [177Lu]Lu-PSMA-617 Radioligand Therapy (
PSMA-617-100
)
radioligand,PSMA-targeting
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
ACTRN12623001072606
Radonc
Phase 1
Recruiting
A phase 1a/b dose-escalation and dose-expansion study to evaluate Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC) (
LuCape
)
fluoropyrimidine
radioconjugate,PSMA-targeting
Castrate-resistant prostate cancer
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12623000216617
Radonc
Phase 1
Not yet recruiting
A pilot, feasibility study of 177Lu-DOTA-Rosopatamab (TLX591) therapy in castrate resistant prostate adenocarcinoma patients showing progression on radioligand therapy using PSMA small molecule ligands (
RESCUE
)
radioligand,PSMA-targeting
Prostate cancer
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12623000073606
Radonc
Phase 0
Not yet recruiting
A Single-Arm, Open-Label, Prospective, Phase 0 Trial Evaluating the Safety and Efficacy of Salvage 177Lu-PSMA-I&T in Prostate Specific Antigen (PSA) Biochemical Failure After Radical Prostatectomy for High-Risk Prostate Cancer (
SLAP-trial
)
radioconjugate,PSMA-targeting
Prostate cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
ACTRN12622001378718
Radonc
Phase 1 / Phase 2
Recruiting
Phase I/IIa Dose Escalation and Toxicity Study of [212Pb]Pb-ADVC001 in Metastatic Prostate Adenocarcinoma (TheraPb – Phase I/II) (
TheraPb-phase-I-II
)
radioligand,PSMA-targeting
Prostate cancer
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12618001667202
Radonc
Phase 3
Not yet recruiting
A Randomised Trial of External Beam Radiation Therapy (EBRT) Alone versus EBRT in Combination with 177Lu-PSMA Theranostic in Patients with Biochemically Recurrent Prostate Cancer (to determine the proportion of participants in each group with a 50% decline in PSA through to the end of the trial) - a phase 3 study (
TARGET
)
radioconjugate,PSMA-targeting
radiotherapy
Prostate cancer
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (12)
Not yet recruiting (3)
Recruitment Country and State
NSW (7)
QLD (6)
VIC (6)
WA (5)
SA (3)
NZ (2)
Phase
Phase 0 (1)
Phase 1 (6)
Phase 1 / Phase 2 (3)
Phase 2 (1)
Phase 3 (3)
Trial Type
Radonc (12)
Advanced (3)
Cancer Therapy Class
PSMA
100%
AR
20%
androgen axis
20%
PARP
7%
CYP17A1
7%
Facility
4102 - Woolloongabba - Princess Alexandra Hospital (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (4)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
2109 - North Ryde - Macquarie University Hospital (1)
4509 - North Lakes - Icon Cancer Centre North Lakes (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
3002 - East Melbourne - Epworth Freemasons (1)
6150 - Murdoch - St John of God Murdoch Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
6009 - Nedlands - Linear Clinical Research (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
Cancer Type
Cancer
Male genital cancers
Prostate cancer
Solid tumour
Urogenital cancer
Castrate-resistant prostate cancer
Prostate adenocarcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy